Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I believe the shorts were trying to get a volatility halt on downward momentum on that raid
The only time PPS is important is when exercising warrants or options
Plus @ $50.00 pps he has another 250-270K to pocket LOL
Then it will be "hold the $50.00 pps for 60 days" LOL
Well, this is certainly going to burst some bubbles for the Labor day weekend.
Securities Atty. I used one against Ameritrade back in the day
Aren't these "self directing" accounts? Yes they are! So they in essence are telling us how to direct our accounts according to their dictates
Very intriguing. I wonder if they are looking for a fall rollout?
(8>)
Mr Dimon is such a thoughtful, caring man. He really wants to help those who have nothing to show for the escrows
Hi stuff. Hope all is well with you. Yes, hot and sticky, yuk! Have a blessed evening
I think that earns a ban?
Put my US Flag at half staff until Americans are brought home
Adhera Therapeutics Signs Exclusive License Agreement with Melior Pharmaceuticals I for New Type 1 Diabetes Drug Candidate
Adhera to develop MLR-1023 as a new drug for Type I diabetes with a focus on C-peptide positive patients (~320,000 – 480,000 patients in U.S.)
Laboratory and clinical research support MLR-1023 as the world’s first safe, effective beta cell proliferative agent
Adhera will leverage existing data to initiate a Phase 2 trial in Type 1 diabetes patients
Baton Rouge, LA, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce that the Company has executed an exclusive license agreement with Melior Pharmaceuticals I, Inc. (“Melior Pharma 1”) defining the terms and conditions for which Adhera will license MLR-1023 (tolimidone) from Melior Pharma 1 for the purpose of developing a novel therapeutic for Type 1 diabetes.
MLR-1023, a lyn kinase activator, has demonstrated exceptional clinical safety and tolerability in over 700 patients in Phase 2a and Phase 2b Type 2 diabetes studies. Adhera will focus its initial clinical trials on patients with Type 1 diabetes where the Company can benefit from a number of factors, including the existing safety profile to move directly into Phase 2 clinical trials, a shorter and less expensive clinical pathway compared to Type 2 diabetes, independent research demonstrating a robust therapeutic effect by MLR-1023 in a Type 1 diabetes animal model, and large addressable market due to the lack of alternative treatment options in Type 1 diabetes aside from insulin injections or an insulin pump.
In Type 1 diabetes patients, the pancreas produces little to no insulin. At a cellular level, the immune system attacks pancreatic beta cells that produce insulin, leaving the patient with deficient levels of insulin to control blood glucose and dependency upon exogenous insulin. Approximately 20-30 percent of Type 1 diabetes patients have demonstratable amounts of beta cell mass as determined by detectable amount of the insulin synthesis byproduct, C-peptide. Research indicates the potential for MLR-1023 to induce proliferation of a patient’s remaining beta cells. Melior and Adhera hypothesize that if the beta cell mass can be expanded in the C-peptide positive patient population, it may be possible to either reduce or eliminate the exogenous insulin requirement.
“MLR-1023 could represent a major leap forward in diabetes care, particularly for the 320,000-480,000 people in the U.S. expressing C-peptide that indicates they have residual levels of functional beta cells,” said Andrew Kucharchuk, Chief Executive Officer at Adhera Therapeutics. “Researchers have for a number of years tried unsuccessfully to identify a safe and well tolerated agent that induces replication of human beta cells. MLR-1023 could be the first to do so. Clinical trials have demonstrated MLR-1023 as an insulin sensitizer and we greatly look forward to initiating a Phase 2 trial to evaluate it as an inducer of beta cell replication.”
The license agreement is the second between Adhera and the Melior family of companies. On July 29, 2021, Adhera announced a license agreement pursuant to which the Company licensed MLR-1019 (armesocarb) from Melior Pharma 2, for the initial purpose of developing a new therapeutic for Parkinson’s disease. The Company expects to provide additional updates on this initiative in the coming weeks.
About Type 1 Diabetes
According to the Juvenile Diabetes Research Foundation, approximately 1.6 million Americans are living with Type 1 diabetes, including about 200,000 youth (less than 20 years old) and 1.4 million adults (20 years old and older). By 2050, the prevalence is expected to rise to 5 million people in the U.S., including nearly 600,000 youth. There are $16 billion in Type 1 diabetes-associated healthcare expenditures and lost income annually in the U.S. Less than one-third of people with Type 1 diabetes in the U.S. are consistently achieving target blood-glucose control levels.
About Adhera Therapeutics
Adhera Therapeutics is a clinical stage biopharmaceutical company focused on identifying advanced drug candidates that may qualify for accelerated developmental pathways. Adhera’s legacy assets include CEQ508, an oral delivery of small interfering RNA (siRNA) against beta-catenin, to suppress polyps in the precancerous syndrome and orphan indication Familial Adenomatous Polyposis (FAP). In addition to MLR-1019 (armesocarb), which is being developed for the treatment of Parkinson’s Disease, the Company is actively exploring additional pipeline additions.
About Melior
Melior Discovery and its companies, Melior Pharmaceuticals I, Inc. and Melior Pharmaceuticals II, LLC, are leaders in pharmaceutical drug repositioning using the unique theraTRACE ® platform comprised of multiplexed in vivo disease models. Melior is using these capabilities to build an internal pipeline of development candidates and also partners with pharmaceutical and biopharmaceutical companies to apply the theraTRACE ® platform and its in-depth in vivo pharmacology expertise to their development candidates. Melior Discovery and Melior Pharmaceuticals are privately held and located in Exton, PA. For more information, visit www.meliordiscovery.com and www.meliorpharma.com .
ATRX news: Adhera Therapeutics Signs Exclusive License Agreement with Melior Pharmaceuticals I for New Type 1 Diabetes Drug Candidate
Adhera to develop MLR-1023 as a new drug for Type I diabetes with a focus on C-peptide positive patients (~320,000 – 480,000 patients in U.S.)
Laboratory and clinical research support MLR-1023 as the world’s first safe, effective beta cell proliferative agent
Adhera will leverage existing data to initiate a Phase 2 trial in Type 1 diabetes patients
Baton Rouge, LA, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce that the Company has executed an exclusive license agreement with Melior Pharmaceuticals I, Inc. (“Melior Pharma 1”) defining the terms and conditions for which Adhera will license MLR-1023 (tolimidone) from Melior Pharma 1 for the purpose of developing a novel therapeutic for Type 1 diabetes.
MLR-1023, a lyn kinase activator, has demonstrated exceptional clinical safety and tolerability in over 700 patients in Phase 2a and Phase 2b Type 2 diabetes studies. Adhera will focus its initial clinical trials on patients with Type 1 diabetes where the Company can benefit from a number of factors, including the existing safety profile to move directly into Phase 2 clinical trials, a shorter and less expensive clinical pathway compared to Type 2 diabetes, independent research demonstrating a robust therapeutic effect by MLR-1023 in a Type 1 diabetes animal model, and large addressable market due to the lack of alternative treatment options in Type 1 diabetes aside from insulin injections or an insulin pump.
In Type 1 diabetes patients, the pancreas produces little to no insulin. At a cellular level, the immune system attacks pancreatic beta cells that produce insulin, leaving the patient with deficient levels of insulin to control blood glucose and dependency upon exogenous insulin. Approximately 20-30 percent of Type 1 diabetes patients have demonstratable amounts of beta cell mass as determined by detectable amount of the insulin synthesis byproduct, C-peptide. Research indicates the potential for MLR-1023 to induce proliferation of a patient’s remaining beta cells. Melior and Adhera hypothesize that if the beta cell mass can be expanded in the C-peptide positive patient population, it may be possible to either reduce or eliminate the exogenous insulin requirement.
“MLR-1023 could represent a major leap forward in diabetes care, particularly for the 320,000-480,000 people in the U.S. expressing C-peptide that indicates they have residual levels of functional beta cells,” said Andrew Kucharchuk, Chief Executive Officer at Adhera Therapeutics. “Researchers have for a number of years tried unsuccessfully to identify a safe and well tolerated agent that induces replication of human beta cells. MLR-1023 could be the first to do so. Clinical trials have demonstrated MLR-1023 as an insulin sensitizer and we greatly look forward to initiating a Phase 2 trial to evaluate it as an inducer of beta cell replication.”
The license agreement is the second between Adhera and the Melior family of companies. On July 29, 2021, Adhera announced a license agreement pursuant to which the Company licensed MLR-1019 (armesocarb) from Melior Pharma 2, for the initial purpose of developing a new therapeutic for Parkinson’s disease. The Company expects to provide additional updates on this initiative in the coming weeks.
About Type 1 Diabetes
According to the Juvenile Diabetes Research Foundation, approximately 1.6 million Americans are living with Type 1 diabetes, including about 200,000 youth (less than 20 years old) and 1.4 million adults (20 years old and older). By 2050, the prevalence is expected to rise to 5 million people in the U.S., including nearly 600,000 youth. There are $16 billion in Type 1 diabetes-associated healthcare expenditures and lost income annually in the U.S. Less than one-third of people with Type 1 diabetes in the U.S. are consistently achieving target blood-glucose control levels.
About Adhera Therapeutics
Adhera Therapeutics is a clinical stage biopharmaceutical company focused on identifying advanced drug candidates that may qualify for accelerated developmental pathways. Adhera’s legacy assets include CEQ508, an oral delivery of small interfering RNA (siRNA) against beta-catenin, to suppress polyps in the precancerous syndrome and orphan indication Familial Adenomatous Polyposis (FAP). In addition to MLR-1019 (armesocarb), which is being developed for the treatment of Parkinson’s Disease, the Company is actively exploring additional pipeline additions.
About Melior
Melior Discovery and its companies, Melior Pharmaceuticals I, Inc. and Melior Pharmaceuticals II, LLC, are leaders in pharmaceutical drug repositioning using the unique theraTRACE ® platform comprised of multiplexed in vivo disease models. Melior is using these capabilities to build an internal pipeline of development candidates and also partners with pharmaceutical and biopharmaceutical companies to apply the theraTRACE ® platform and its in-depth in vivo pharmacology expertise to their development candidates. Melior Discovery and Melior Pharmaceuticals are privately held and located in Exton, PA. For more information, visit www.meliordiscovery.com and www.meliorpharma.com .
Doing great here in good ol KY!. Can't imagine having the skeeters that bad. I'd be wearing some sort of repellant all the time
Good morning Larry. Yes, going to be an uncomfortable day outside. Glad I am not still doing lawncare/landscaping, those were the days I hated most lol
They were always pretty bad by Earl lake where we lived.
That is my conclusion. Failure to meet specific dates for claims would be disallowed
Put your boots on folks, it's gettin deep. lol
Full steam ahead
This is such huge news. Pennies coming imo
LIGA has had some of the biggest challenges any small developing company could ever face, including:
The IRS lien for $1.5 million that took over 18 months to defeat AND ended up with a $3 million tax loss carry forward.
LIGA had people associated with old management try to sabotage LIG Assets stock and thanks to the SEC, we saw 56 federal indictments filed against them.
Others did everything to block deals and cost the company hundreds of thousands in fees, interest, etc. ... and most of those relationships have been severed and the remaining are in the hands of our attorney for proper legal pursuit.
Please, someone tell my poor lonely escrows (which are loving me less and less as time goes by) that. Just sayin (;>}
Now, let's start seeing some progress to get LIGA moving forward. There has never been a better time for real estate or housing. Seize the moment!
My LIGA shares are getting so old, I may be able to collect Social Security on them soon
COOP was the tell, because it (COOP shares) was the only way peeps were going to make anything back.
Right on, right on, right on
Notice how the shift is ever so slightly happening. Be happy that COOP has gone up 100+%. Escrows- it is what it is LOL
Yup. I hear Bill Cosby's cell is free lol
Heat was on, I'm sure
Since liberals have no moral compass, it takes longer.
"Love the one you're with" Cuomo resigns on CNBC. Effective in 14 days https://www.cnbc.com/2021/08/10/cuomo-resigns-as-governor-of-new-york-over-sexual-harassment-scandal.html
No problem
Maybe we need to speed up the Global warming to hasten the process (;>)
OK Chicken Little